- Details
- Marc-Oliver Grimm joins Pedro Barata in a discussion on the final results of the TITAN-RCC trial, assessing a tailored approach to systemic therapy in patients with metastatic renal cell carcinoma (mRCC). The TITAN-RCC was designed many years ago, when nivolumab + ipilimumab (NIVO/IPI) was not approved yet as a first-line treatment. During this time the pivotal CheckMate 214 trial was still in pro...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss an update on the CARMENA trial. CARMENA was a phase III trial in 450 patients with metastatic renal cell carcinoma (mRCC) enrolled from 2009 to 2017. The objective of this study was to provide updated overall survival (OS) outcomes of CARMENA and assess whether some subgroups may still benefit from upfront cytoreductive nephrectomy. Biographies: Chri...
|
- Details
- Pedro Barata sits down with David Cella to unpack the critical findings of the CheckMate 214 study. Focused on the treatment of advanced renal cell carcinoma, the study compares the efficacy and patient-reported quality of life between the combination therapy of nivolumab and ipilimumab against sunitinib. Dr. Cella emphasizes that not only does the combination therapy improve overall survival and...
|
- Details
- Axel Bex joins Alicia Morgans to discuss the results of the NeoAvAx trial examining neoadjuvant avelumab and axitinib following nephrectomy for patients who are at high risk for recurrence. The NeoAvAx trial tests the neoadjuvant use of a combination of the immune checkpoint inhibitor avelumab and the VEGF-inhibitor axitinib. Biographies: Axel Bex, MD, PhD, Urologic Surgeon, Royal Free London NHS...
|
- Details
- Medical Oncologist and member of the scientific committee of the upcoming European International Kidney Cancer Symposium, Samra Turajlic joins Rana McKay to discuss the upcoming IKCS meeting being held April 22nd through the 24th in Antwerpen, Belgium. The program will consist of Award Lectures in Urology and Oncology, Basic Science in renal cell carcinoma (RCC), Biomarkers in RCC, Diagnostics, an...
|
- Details
- Alicia Morgans is joined by Toni Choueiri to discuss his GU ASCO 2022 presentation on a 30-month follow-up from the KEYNOTE-564 trial of post-nephrectomy adjuvant pembrolizumab in patients with renal cell carcinoma (RCC). Dr. Choueiri highlights that adjuvant pembrolizumab continued to demonstrate a disease-free survival (DFS) benefit following nephrectomy for patients with intermediate-high or hi...
|
- Details
- Alicia Morgans engages with Thomas Powles to discuss the 42-month follow-up data from the KEYNOTE-426 study, a phase 3 randomized trial examining the efficacy of axitinib and pembrolizumab versus sunitinib for metastatic kidney cancer. Dr. Powles elaborates on the study's results, which indicate that the combination therapy has been effective, particularly in terms of progression-free survival (PF...
|
- Details
- At the 2021 ASCO GU Cancers Symposium, Dr Robert Motzer and colleagues presented the results of the CLEAR study examining first-line lenvatinib and everolimus or lenvatinib and pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma and concurrent with the presentation, CLEAR was published in the New England Journal of Medicine. In this UroToday Journal Club, Christopher Wall...
|
- Details
- In this conversation, Rana McKay and Andrea Apolo highlight several studies presented during the ASCO 2021 Annual Meeting on combination therapeutic options for advanced renal cell carcinoma (RCC). Dr. Apolo expands on several studies she highlighted in her presentation and where these treatment options fit into the treatment landscape of advanced RCC potentially enhancing the immune effect of imm...
|
- Details
- Following the Presidential Symposium presentation at the European Society of Medical Oncology (ESMO) 2020 Virtual Annual Meeting, Toni Choueiri, MD, joins Alicia Morgans, MD, MPH and discusses the CheckMate—9ER phase III, open-label, international randomized controlled trial among patients with previously untreated, histologically confirmed advanced or metastatic renal cell carcinoma with a clear...
|